Valhalla Ventures

Huge congrats to Valhalla Ventures portfolio company Rimac Automobili on the announcement of its new car, the BUGATTI Tourbillon!

I am thrilled to announce that Valhalla Ventures portfolio company, Terran Biosciences, has introduced TerXT, a breakthrough combination of the prodrugs of xanomeline and trospium for the treatment of schizophrenia. This innovation comes after the recent acquisition of KarXT, a prominent schizophrenia drug comprising xanomeline and trospium, by pharma giant BMS ($BMY) in a significant $14B deal. Stay tuned for the impact of this development on the industry! #terranbiosciences #valhallaventures #bristolmyerssquibb #karuna

Today, we’re excited to announce the development of TerXT, a combination of novel prodrugs of xanomeline and trospium designed to be long-acting treatments for schizophrenia. Using a novel prodrug approach we’ve been able to overcome inherent pharmacokinetic and physical property limitations of xanomeline and trospium with the goal of creating fixed-dose combinations for daily oral administration as well as long-acting intramuscular injection with multi-month duration. The original combination of xanomeline and trospium has been shown in recent trials to be an effective therapeutic for schizophrenia and is currently undergoing FDA review via the 505(b)(1) pathway. If approved, Terran plans to use the rapid 505(b)(2) approval pathway for our next-generation prodrug forms, potentially enabling market entry approximately five years after the initial xanomeline/trospium approval. This milestone is the result of tireless efforts by over 200 chemists who designed and synthesized 500 prodrugs, which were then tested in 285 in vitro and 365 in vivo studies to select the lead prodrug forms with optimized properties for long-acting administration. Terran has also now received notice of patent claims found to be allowable from the United States Patent and Trademark Office for the composition of matter for the world’s first prodrugs of xanomeline. The development of TerXT represents a major step in Terran’s mission to create effective, accessible, affordable, and patient-friendly neuropsychiatric therapies through innovative drug design and regulatory strategies. Read the press release here: https://bit.ly/4dI3OQy #schizophrenia #mentalhealth #drugdevelopment

Neel Kunjur and Karan Kunjur sat down with Aria Alamalhodaei from TechCrunch to discuss new contracts, funding and hardware development. The future platform in space has higher power, can handle higher orbits, and can be delivered rapidly - filling a significant gap in our current industrial base. https://lnkd.in/g_VnhCvJ

The current model for deep space infrastructure and transport is painfully expensive because it depends on throwing rockets away for almost all missions. Missions could be 10x cheaper - and reusable - if they had access to propellants produced on the Moon and Mars. That’s what we are solving at Starpath - and we are incredibly excited to be out of stealth! Join the team: hello@starpath.space https://lnkd.in/g7fe9N3U